Clinical Trial Update: First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study evaluating the safety and immunogenicity of RSV vaccine candidates SCB-1019 and SCB-1019T in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• SCB-1019 (SCB-1019)
• SCB-1019T

Snippet

Sponsor: Clover Biopharmaceuticals AUS Pty | Conditions: Respiratory Syncytial Virus Vaccination | Phase 1 | Status: COMPLETED